WOCKHARDT LTD. Q4 FY26 Results

Summary

Wockhardt Limited reported a strong financial performance for Q4 and the full Financial Year 2026, marking a significant return to profitability. The company achieved a positive Profit before Tax of ₹238 crore for FY26, reversing a loss from the prior year. Q4 FY26 also saw robust growth, with revenue increasing by 30% to ₹965 crore and EBITDA soaring by 147% to ₹196 crore. For the full year, revenue grew 11% to ₹3,373 crore, while EBITDA improved by 51% to ₹630 crore, supported by healthy EBITDA margins of 18.7% for FY26. The Biotech segment was a key driver, exhibiting substantial growth, and the company is strategically focused on expanding its diabetes care portfolio with the planned launch of Insulin analogs.

Key Highlights

1. 1

   Wockhardt Limited reported a positive Profit before Tax (PBT) of ₹238 crore for the full Financial Year 2026, a significant turnaround from a loss of ₹(16) crore in the previous year.

2. 2

   For Q4 FY26, the company's PBT stood at ₹189 crore, compared to a loss of ₹(22) crore in Q4 FY25, indicating strong quarterly performance.

3. 3

   Full-year FY26 revenue grew by 11% to ₹3,373 crore, up from ₹3,033 crore in FY25.

4. 4

   Q4 FY26 revenue saw a substantial 30% growth year-over-year, reaching ₹965 crore.

5. 5

   EBITDA for Q4 FY26 surged by 147% to ₹196 crore, contributing to a full-year EBITDA of ₹630 crore, which represents a 51% increase over FY25.

6. 6

   The overall Biotech operations demonstrated robust growth, with a 126% increase to ₹252 crore in Q4 FY26 and a 27% growth to ₹697 crore for the full year, primarily driven by emerging markets.

7. 7

   The company anticipates a significant business opportunity with the upcoming launch of Insulin analogs over the next few years, reinforcing its commitment to global diabetes healthcare.